Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.51 |
| ▸ | DRD2 | P14416 | 9/20 | 0.41 |
| ▸ | DRD3 | P35462 | 9/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 6/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23981044 | 0.91 | GLP1R (0.44) | GLP1RDRD2DRD3GRM2HTR2A | |
| SCHEMBL25815408 | 0.87 | GLP1R (0.56) | GLP1RKCNH2 | |
| SCHEMBL23980868 | 0.86 | GLP1R (0.47) | GLP1RDRD2DRD3GRM2KCNH2 | |
| SCHEMBL23981043 | 0.84 | GLP1R (0.45) | GLP1R | |
| SCHEMBL23980930 | 0.84 | GLP1R (0.50) | GLP1RDRD2DRD3GRM2KCNH2 | |
| SCHEMBL23980950 | 0.83 | GLP1R (0.51) | GLP1RDRD2DRD3GRM2DRD4 | |
| SCHEMBL23980923 | 0.83 | GLP1R (0.48) | GLP1RDRD2DRD3GRM2HTR2A | |
| SCHEMBL23980830 | 0.83 | GLP1R (0.57) | GLP1RDRD2DRD3GRM2 | |
| SCHEMBL23981029 | 0.82 | GLP1R (0.50) | GLP1RDRD2DRD3GRM2HTR2A | |
| SCHEMBL23981022 | 0.82 | GLP1R (0.52) | GLP1RDRD2DRD3GRM2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2021219019-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | GLP1R 1/4885DRD2 2267/4885DRD3 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.